Prospective Grant of an Exclusive Patent License: Development and Commercialization of Natural Killer Cell Therapies for Cancer, 80556-80565 [2022-28404]
Download as PDF
80556
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Dental and Craniofacial Research Council.
Date: January 25, 2023.
Open: 10:00 a.m. to 2:00 p.m.
Agenda: Report of the Director, NIDCR and
concept clearances.
Place: National Institute of Dental and
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Closed: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Dental and
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Lynn M. King, Ph.D.,
Executive Secretary, Division of Extramural
Activities, National Institute of Dental and
Craniofacial Research, 6701 Democracy
Blvd., Room 960, Bethesda, MD 20892–4878,
(301) 594–5006, Lynn.King@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program No. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: December 27, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–28448 Filed 12–29–22; 8:45 am]
BILLING CODE 4140–01–P
khammond on DSKJM1Z7X2PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Natural Killer
Cell Therapies for Cancer
AGENCY:
National Institutes of Health,
HHS.
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to Replay Holdings
LLC (‘‘Replay’’) located in San Diego,
California.
SUMMARY:
Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before January 17, 2023 will be
considered.
DATES:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Suna Gulay French,
Technology Transfer Manager,
Telephone: (240) 276–7424; Email:
suna.gulay@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
Group A
1. United States Provisional Patent
Application No. 62/084,654 filed
November 26, 2014, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–0–US–01];
2. PCT Patent Application No. PCT/
US2015/062269 filed November 24,
2015, entitled ‘‘Anti-Mutated KRAS T
Cell Receptors’’ [HHS Reference No. E–
028–2015–1–PCT–01];
3. Australian Patent No. 2015353720
issued June 11, 2020, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–AU–02];
4. Canadian Patent Application No.
2,968,399 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–CA–03];
5. Chinese Patent No.
ZL201580070673.7 issued November 16,
2021, entitled ‘‘Anti-Mutated KRAS T
Cell Receptors’’ [HHS Reference No. E–
028–2015–1–CN–04];
6. European Patent No. 3223850
issued January 8, 2020, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–EP–05];
a. Validated in the following
jurisdictions: AT, BE, CH, CZ, DE, ES,
FR, GB, GR, IE, IT, NL, NO, PL, PT, SE,
SI, SK, TR;
7. Israeli Patent No. 252258 issued
March 2, 2022, entitled ‘‘Anti-Mutated
KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–IL–06];
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
8. Japanese Patent No. 6863893 issued
April 5, 2021, entitled ‘‘Anti-Mutated
KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–JP–07];
9. Korean Patent Application No.
2017–7017289 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–KR–08];
10. Mexican Patent No. 384919 issued
July 29, 2021, entitled ‘‘Anti-Mutated
KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–MX–09];
11. New Zealand Patent Application
No. 732045 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–NZ–10];
12. Saudi Arabian Patent No. 7697
issued March 11, 2021, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–SA–11];
13. Singapore Patent Application No.
11201704155U effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–SG–12];
14. United States Patent No.
11,207,394 issued December 28, 2021,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–US–13];
15. Hong Kong Patent No. 1243642
issued January 22, 2021, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–HK–14];
16. European Patent Application No.
20150279.6 filed January 3, 2020,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–EP–15];
17. Singapore Patent Application No.
10201913978R filed December 31, 2019,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–SG–16];
18. Australian Patent Application No.
2020203465 filed May 26, 2020, entitled
‘‘Anti-Mutated KRAS T Cell Receptors’’
[HHS Reference No. E–028–2015–1–
AU–36];
19. Saudi Arabian Patent Application
No. 520420365 filed October 15, 2020,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–SA–37];
20. Hong Kong Patent Application No.
42020021375.9 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–HK–38];
21. Japanese Patent Application No.
2021–063092 filed April 1, 2021,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–JP–40];
22. Chinese Patent Application No.
202111263859.8 filed October 27, 2021,
entitled ‘‘Anti-Mutated KRAS T Cell
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
Receptors’’ [HHS Reference No. E–028–
2015–1–CN–41];
23. United States Patent Application
No. 17/535,318 filed November 24,
2021, entitled ‘‘Anti-Mutated KRAS T
Cell Receptors’’ [HHS Reference No. E–
028–2015–1–US–42];
24. Hong Kong Patent Application No.
42022054674.1 filed June 27, 2022,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–HK–43];
25. United States Provisional Patent
Application No. 62/171,321 filed June 5,
2015, entitled ‘‘Anti-Mutated KRAS T
Cell Receptors’’ [HHS Reference No. E–
180–2015–0–US–01];
26. United States Provisional Patent
Application No. 62/218,688 filed
September 15, 2015, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–US–01];
27. PCT Patent Application No. PCT/
US2016/050875 filed September 9,
2016, entitled ‘‘T Cell Receptors
Recognizing HLA–CW8 Restricted
Mutated KRAS’’ [HHS Reference No. E–
265–2015–0–PCT–02];
28. Australian Patent No. 2016323017
issued February 25, 2021, entitled ‘‘T
Cell Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–AU–03];
29. Canadian Patent Application No.
2,998,869 effective filing date of
September 9, 2016, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–CA–04];
30. Chinese Patent No.
ZL201680058891.3 issued October 8,
2021, entitled ‘‘T Cell Receptors
Recognizing HLA–CW8 Restricted
Mutated KRAS’’ [HHS Reference No. E–
265–2015–0–CN–05];
31. European Patent No. 3350213
issued March 31, 2021, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–EP–06];
a. Validated in the following
jurisdictions: BE, CH, DE, DK, ES, FR,
GB, IE, IT, NL, NO and SE.
32. Israeli Patent Application No.
257840 effective filing date of
September 9, 2016, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–IL–07];
33. Japanese Patent Application No.
2018–513423 effective filing date of
September 9, 2016, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–JP–08];
34. Korean Patent Application No.
2018–7010326, effective filing date of
September 9, 2016, entitled ‘‘T Cell
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–KR–09];
35. Mexican Patent Application No.
MX/a/2018/003062 effective filing date
of September 9, 2016, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–MX–10];
36. New Zealand Patent Application
No. 740714 effective filing date of
September 9, 2016, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–NZ–11];
37. Saudi Arabian Patent Application
No. 518391109 effective filing date of
September 9, 2016, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–SA–12];
38. Singapore Patent No.
11201802069U issued March 31, 2022,
entitled ‘‘T Cell Receptors Recognizing
HLA–CW8 Restricted Mutated KRAS’’
[HHS Reference No. E–265–2015–0–SG–
13];
39. United States Patent No.
10,556,940 issued February 11, 2020,
entitled ‘‘T Cell Receptors Recognizing
HLA–CW8 Restricted Mutated KRAS’’
[HHS Reference No. E–265–2015–0–US–
14];
40. Hong Kong Patent No. HK1257902
issued December 24, 2021, entitled ‘‘T
Cell Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–HK–15];
41. United States Patent Application
No. 16/739,310 filed January 10, 2020,
entitled ‘‘T Cell Receptors Recognizing
HLA–CW8 Restricted Mutated KRAS’’
[HHS Reference No. E–265–2015–0–US–
16];
42. Singapore Patent Application No.
10201913868X filed December 30, 2019,
entitled ‘‘T Cell Receptors Recognizing
HLA–CW8 Restricted Mutated KRAS’’
[HHS Reference No. E–265–2015–0–SG–
17];
43. Australian Patent No. 2021200833
issued August 18, 2022, entitled ‘‘T Cell
Receptors Recognizing HLA–CW8
Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–AU–18];
44. European Patent Application No.
21162567.8 filed March 15, 2021,
entitled ‘‘T Cell Receptors Recognizing
HLA–CW8 Restricted Mutated KRAS’’
[HHS Reference No. E–265–2015–0–EP–
19];
45. Saudi Arabian Patent Application
No. 521421309 filed February 23, 2021,
entitled ‘‘T Cell Receptors Recognizing
HLA–CW8 Restricted Mutated KRAS’’
[HHS Reference No. E–265–2015–0–SA–
20];
46. Chinese Patent Application No.
202111083392.9 filed September 15,
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
80557
2021, entitled ‘‘T Cell Receptors
Recognizing HLA–CW8 Restricted
Mutated KRAS’’ [HHS Reference No. E–
265–2015–0–CN–33];
47. New Zealand Patent Application
No. 779633 filed September 2, 2021,
entitled ‘‘T Cell Receptors Recognizing
HLA–CW8 Restricted Mutated KRAS’’
[HHS Reference No. E–265–2015–0–
NZ–34];
48. Australian Patent Application No.
2022209229 filed July 26, 2022, entitled
‘‘T Cell Receptors Recognizing HLA–
CW8 Restricted Mutated KRAS’’ [HHS
Reference No. E–265–2015–0–AU–35];
49. United States Provisional Patent
Application No. 62/369,883 filed
August 2, 2016, entitled ‘‘Anti-KRAS
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–US–01];
50. PCT Patent Application No. PCT/
US2017/044615 filed July 31, 2017,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–PCT–02];
51. Australian Patent Application No.
2017306038 effective filing date of July
31, 2017, entitled ‘‘Anti-KRAS G12D T
Cell Receptors’’ [HHS Reference No. E–
175–2016–0–AU–03];
52. Canadian Patent Application No.
3,032,870 effective filing date of July 31,
2017, entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–CA–04];
53. Chinese Patent Application No.
201780059356.4 effective filing date of
July 31, 2017, entitled ‘‘Anti-KRAS
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–CN–05];
54. European Patent No. 3494133
issued July 6, 2022, entitled ‘‘AntiKRAS G12D T Cell Receptors’’ [HHS
Reference No. E–175–2016–0–EP–06];
a. Validated in the following
jurisdictions: AL, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
HR, IE, IS, IT, LT, LU, LV, MC, MK, MT,
NL, NO, PL, PT, RO, RS, SE, SI, SK, SM
and TR.
55. Japanese Patent Application No.
2019–505220 effective filing date of July
31, 2017, entitled ‘‘Anti-KRAS G12D T
Cell Receptors’’ [HHS Reference No. E–
175–2016–0–JP–07];
56. United States Patent No.
10,611,816 issued April 7, 2020, entitled
‘‘Anti-KRAS G12D T Cell Receptors’’
[HHS Reference No. E–175–2016–0–US–
08];
57. Israeli Patent Application No.
264425 effective filing date of July 31,
2017, entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–IL–09];
58. Korean Patent Application No.
2019–7005837 effective filing date of
July 31, 2017, entitled ‘‘Anti-KRAS
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
80558
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–KR–10];
59. Singapore Patent Application No.
11201900654Q effective filing date of
July 31, 2017, entitled ‘‘Anti-KRAS
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–SG–11];
60. Hong Kong Patent Application No.
19133082.8 effective filing date of July
31, 2017, entitled ‘‘Anti-KRAS G12D T
Cell Receptors’’ [HHS Reference No. E–
175–2016–0–HK–12];
61. Hong Kong Patent Application No.
19132196.7 effective filing date of July
31, 2017, entitled ‘‘Anti-KRAS G12D T
Cell Receptors’’ [HHS Reference No. E–
175–2016–0–HK–13];
62. Singapore Patent Application No.
10201913959W filed December 31,
2019, entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–SG–14];
63. United States Patent No.
11,208,456 issued December 28, 2021,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–US–15];
64. United States Patent Application
No. 17/345,390 filed June 11, 2021,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–US–16];
65. United States Patent Application
No. 17/541,619 filed December 3, 2021,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–US–17];
66. Japanese Patent Application No.
2021–199878 filed December 9, 2021,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–JP–18];
67. European Patent Application No.
22182473.3 filed July 1, 2022, entitled
‘‘Anti-KRAS G12D T Cell Receptors’’
[HHS Reference No. E–175–2016–0–EP–
19];
68. United States Provisional Patent
Application No. 62/560,930 filed
September 20, 2017, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–US–01];
69. PCT Patent Application No. PCT/
US2018/051641 filed September 19,
2018, entitled ‘‘HLA Class II-Restricted
T Cell Receptors Against Mutated RAS’’
[HHS Reference No. E–181–2017–0–
PCT–02];
70. Argentina Patent Application No.
P180102695 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–AR–03];
71. Taiwanese Patent Application No.
107133221 filed September 20, 2018,
entitled ‘‘HLA Class II-Restricted T Cell
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
Receptors Against Mutated RAS’’ [HHS
Reference No. E–181–2017–0–TW–05];
72. United States Patent No.
11,306,132 issued April 19, 2022,
entitled ‘‘HLA Class II-Restricted T Cell
Receptors Against Mutated RAS’’ [HHS
Reference No. E–181–2017–0–US–06];
73. Australian Patent Application No.
2018335274 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–AU–07];
74. Brazilian Patent Application No.
BR112020005469–0 effective filing date
of September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–BR–08];
75. Canadian Patent Application No.
3,076,339 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–CA–09];
76. Chinese Patent Application No.
201880060535.4 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–CN–10];
77. Costa Rican Patent Application
No. 2020–0150 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–CR–11];
78. Eurasian Patent Application No.
202090652 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–EA–12];
79. European Patent Application No.
18792591.2 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–EP–13];
80. Israeli Patent Application No.
273254 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–IL–14];
81. Indian Patent Application No.
202047011647 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–IN–15];
82. Japanese Patent Application No.
2020–516422 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–JP–16];
83. Korean Patent Application No.
2020–7011112 effective filing date of
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–KR–17];
84. Mexican Patent Application No.
MX/a/2020/003117 effective filing date
of September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–MX–18];
85. New Zealand Patent Application
No. 762831 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–NZ–19];
86. Singapore Patent Application No.
11202002425P effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–SG–20];
87. Hong Kong Patent Application No.
62020019700.7 effective filing date of
September 19, 2018, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–181–2017–0–HK–21];
88. Brazilian Patent Application No.
BR122021018418–6 filed September 16,
2021, entitled ‘‘HLA Class II-Restricted
T Cell Receptors Against Mutated RAS’’
[HHS Reference No. E–181–2017–0–BR–
22];
89. United States Patent Application
No. 17/692,787 filed March 11, 2022,
entitled ‘‘HLA Class II-Restricted T Cell
Receptors Against Mutated RAS’’ [HHS
Reference No. E–181–2017–0–US–23];
90. United States Provisional Patent
Application No. 62/594,244 filed
December 4, 2017, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–US–01];
91. PCT Patent Application No. PCT/
US2018/063581 filed December 3, 2018,
entitled ‘‘HLA Class I-Restricted T Cell
Receptors Against Mutated RAS’’ [HHS
Reference No. E–239–2017–0–PCT–02];
92. Australian Patent Application No.
2018378200 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–AU–03];
93. Brazilian Patent Application No.
BR112020011111–2 effective filing date
of December 3, 2018, entitled ‘‘HLA
Class I-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–239–2017–0–BR–04];
94. Canadian Application No.
3,084,246 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–CA–05];
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
95. Chinese Application No.
201880087270.7 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–CN–06];
96. Costa Rican Application No.
2020–0287 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–CR–07];
97. Eurasian Application No.
202091335 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–EA–08];
98. European Application No.
18830062.8 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–EP–09];
99. Israeli Application No. 275031
effective filing date of December 3,
2018, entitled ‘‘HLA Class I-Restricted T
Cell Receptors Against Mutated RAS’’
[HHS Reference No. E–239–2017–0–IL–
10];
100. Indian Application No.
202047026991 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–IN–11];
101. Japanese Application No. 2020–
530325 effective filing date of December
3, 2018, entitled ‘‘HLA Class I-Restricted
T Cell Receptors Against Mutated RAS’’
[HHS Reference No. E–239–2017–0–JP–
12];
102. Korean Application No. 2020–
7019185 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–KR–13];
103. Mexican Application No. MX/a/
2020/005765 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–MX–14];
104. New Zealand Application No.
765440 effective filing date of December
3, 2018, entitled ‘‘HLA Class I-Restricted
T Cell Receptors Against Mutated RAS’’
[HHS Reference No. E–239–2017–0–
NZ–15];
105. Singapore Application No.
11202005236Q effective filing date of
December 3, 2018, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–SG–16];
106. United States Patent Application
No. 16/769,144 effective filing date of
December 3, 2018, entitled ‘‘HLA Class
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
I-Restricted T Cell Receptors Against
Mutated RAS’’ [HHS Reference No. E–
239–2017–0–US–17];
107. Hong Kong Patent Application
No. 62021026617.2 effective filing date
of December 3, 2018, entitled ‘‘HLA
Class I-Restricted T Cell Receptors
Against Mutated RAS’’ [HHS Reference
No. E–239–2017–0–HK–18];
108. Brazilian Patent Application No.
BR122021024382–4 filed December 2,
2021, entitled ‘‘HLA Class I-Restricted T
Cell Receptors Against Mutated RAS’’
[HHS Reference No. E–239–2017–0–BR–
19];
109. United States Patent Application
No. 17/931,391 filed September 12,
2022, entitled ‘‘HLA Class I-Restricted T
Cell Receptors Against Mutated RAS’’
[HHS Reference No. E–239–2017–0–US–
20];
110. United States Provisional Patent
Application No. 62/795,203 filed
January 22, 2019, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–US–01];
111. Taiwanese Patent Application
No. 109102511 filed January 22, 2020,
entitled ‘‘HLA Class II-Restricted T Cell
Receptors Against RAS with G12R
Mutation’’ [HHS Reference No. E–029–
2019–0–TW–02];
112. PCT Patent Application No. PCT/
US2020/014382 filed January 21, 2020,
entitled ‘‘HLA Class II-Restricted T Cell
Receptors Against RAS with G12R
Mutation’’ [HHS Reference No. E–029–
2019–0–PCT–03];
113. Australian Patent Application
No. 2020211922 effective filing date of
January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–AU–04];
114. Canadian Patent Application No.
3,127,096 effective filing date of January
21, 2020, entitled ‘‘HLA Class IIRestricted T Cell Receptors Against RAS
with G12R Mutation’’ [HHS Reference
No. E–029–2019–0–CA–05];
115. Chinese Patent Application No.
202080010373.0 effective filing date of
January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–CN–06];
116. European Patent Application No.
20705599.7 effective filing date of
January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–EP–07];
117. Japanese Patent Application No.
2021–542206 effective filing date of
January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–JP–08];
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
80559
118. Korean Patent Application No.
2021–7026169 effective filing date of
January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–KR–09];
119. United States Patent Application
No. 17/424,591 effective filing date of
January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–US–10];
120. Hong Kong Patent Application
No. 62022048432.8 effective filing date
of January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–HK–11];
121. Hong Kong Patent Application
No. 62022047561.5 effective filing date
of January 21, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12R Mutation’’ [HHS
Reference No. E–029–2019–0–HK–12];
122. United States Provisional Patent
Application No. 62/975,544 filed
February 12, 2020, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–US–01];
123. PCT Patent Application No. PCT/
US2021/017794 filed February 12, 2021,
entitled ‘‘HLA Class I-Restricted T Cell
Receptors Against RAS with G12D
Mutation’’ [HHS Ref. No. E–031–2020–
0–PCT–02];
124. Taiwanese Patent Application
No. 110105194 filed February 12, 2021,
entitled ‘‘HLA Class I-Restricted T Cell
Receptors Against RAS with G12D
Mutation’’ [HHS Ref. No. E–031–2020–
0–TW–03];
125. Australian Patent Application
No. 2021221138 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–AU–04];
126. Canadian Patent Application No.
3,168,015 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–CA–05];
127. Chinese Patent Application No.
202180014038.2 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–CN–06];
128. European Patent Application No.
21710730.9 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–EP–07];
129. Indian Patent Application No.
202247050250 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
80560
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–IN–08];
130. Japanese Patent Application No.
2022–548811 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–JP–09];
131. Korean Patent Application No.
2022–7031175 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–KR–10];
132. Singapore Patent Application No.
11202251837Y effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–SG–11];
133. United Kingdom Patent
Application No. 2211733.7 effective
filing date of February 12, 2021, entitled
‘‘HLA Class I-Restricted T Cell
Receptors Against RAS with G12D
Mutation’’ [HHS Ref. No. E–031–2020–
0–GB–12];
134. United States Patent Application
No. 17/799,163 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–US–13];
135. Brazilian Patent Application No.
BR112022015888–2 effective filing date
of February 12, 2021, entitled ‘‘HLA
Class I-Restricted T Cell Receptors
Against RAS with G12D Mutation’’
[HHS Ref. No. E–031–2020–0–BR–14];
136. Chilean Patent Application No.
02208–2022 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–CL–15];
137. Colombian Patent Application
No. NC2022/0012922 effective filing
date of February 12, 2021, entitled
‘‘HLA Class I-Restricted T Cell
Receptors Against RAS with G12D
Mutation’’ [HHS Ref. No. E–031–2020–
0–CO–16];
138. Israeli Patent Application No.
295252 effective filing date of February
12, 2021, entitled ‘‘HLA Class IRestricted T Cell Receptors Against RAS
with G12D Mutation’’ [HHS Ref. No. E–
031–2020–0–IL–18];
139. Mexican Patent Application No.
MX/a/2022/009654 effective filing date
of February 12, 2021, entitled ‘‘HLA
Class I-Restricted T Cell Receptors
Against RAS with G12D Mutation’’
[HHS Ref. No. E–031–2020–0–MX–19];
140. New Zealand Patent Application
No. 790950 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–NZ–20];
141. South African Patent Application
No. 2022/08853 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–ZA–21];
142. Cuban Patent Application No.
2022–0044 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–CU–22];
143. Russian Patent Application No.
2022124004 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–031–2020–0–RU–23];
144. United States Provisional Patent
Application No. 62/976,655 filed
February 14, 2020, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–0–US–01];
145. United States Provisional Patent
Application No. 63/060,340 filed
August 3, 2020, entitled ‘‘HLA Class IRestricted T Cell Receptors Against RAS
with G12V Mutation’’ [HHS Ref. No. E–
190–2020–0–US–01];
146. PCT Patent Application No. PCT/
US2021/017852 filed February 12, 2021,
entitled ‘‘HLA Class I-Restricted T Cell
Receptors Against RAS with G12V
Mutation’’ [HHS Ref. No. E–074–2020–
1–PCT–01];
147. Taiwanese Patent Application
No. 110105193 filed February 12, 2021,
entitled ‘‘HLA Class I-Restricted T Cell
Receptors Against RAS with G12V
Mutation’’ [HHS Ref. No. E–074–2020–
1–TW–02];
148. Australian Patent Application
No. 2021220957 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–AU–03];
149. Canadian Patent Application No.
3,167,382 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–CA–04];
150. Chinese Patent Application No.
202180014281.4 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–CN–05];
151. European Patent Application No.
21710740.8 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–EP–06];
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
152. Indian Patent Application No.
202247050807 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–IN–07];
153. Japanese Patent Application No.
2022–549088 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–JP–08];
154. Korean Patent Application No.
2022–7031589 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–KR–09];
155. Singapore Patent Application No.
11202251947C effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–SG–10];
156. United Kingdom Patent
Application No. 2211757.6 effective
filing date of February 12, 2021, entitled
‘‘HLA Class I-Restricted T Cell
Receptors Against RAS with G12V
Mutation’’ [HHS Ref. No. E–074–2020–
1–GB–11];
157. United States Patent Application
No. 17/799,193 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–US–12];
158. Brazilian Patent Application No.
BR112022015897–1 effective filing date
of February 12, 2021, entitled ‘‘HLA
Class I-Restricted T Cell Receptors
Against RAS with G12V Mutation’’
[HHS Ref. No. E–074–2020–1–BR–13];
159. Mexican Patent Application No.
MX/a/2022/009825 effective filing date
of February 12, 2021, entitled ‘‘HLA
Class I-Restricted T Cell Receptors
Against RAS with G12V Mutation’’
[HHS Ref. No. E–074–2020–1–MX–14];
160. New Zealand Patent Application
No. 791024 effective filing date of
February 12, 2021, entitled ‘‘HLA Class
I-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–074–2020–1–NZ–15];
161. United States Provisional Patent
Application No. 62/981,856 filed
February 26, 2020, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–US–01];
162. PCT Patent Application No. PCT/
US2021/019775 filed February 26, 2021,
entitled ‘‘HLA Class II-Restricted T Cell
Receptors Against RAS with G12V
Mutation’’ [HHS Ref. No. E–088–2020–
0–PCT–02];
163. Taiwanese Patent Application
No. 110106886 filed February 26, 2021,
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
entitled ‘‘HLA Class II-Restricted T Cell
Receptors Against RAS with G12V
Mutation’’ [HHS Ref. No. E–088–2020–
0–TW–03];
164. Australian Patent Application
No. 2021225872 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–AU–04];
165. Canadian Patent Application No.
3,169,086 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–CA–05];
166. Chinese Patent Application No.
202180016761.4 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–CN–06];
167. European Patent Application No.
21712694.5 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–EP–07];
168. Indian Patent Application No.
202247052620 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–IN–08];
169. Korean Patent Application No.
2022–7033222 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–KR–10];
170. Singapore Patent Application No.
1120225235K effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–SG–11];
171. United Kingdom Patent
Application No. 2212195.8 effective
filing date of February 26, 2021, entitled
‘‘HLA Class II-Restricted T Cell
Receptors Against RAS with G12V
Mutation’’ [HHS Ref. No. E–088–2020–
0–GB–12];
172. United States Patent Application
No. 17/802,464 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–US–13];
173. Brazilian Patent Application No.
BR112022016661–3 effective filing date
of February 26, 2021, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
Against RAS with G12V Mutation’’
[HHS Ref. No. E–088–2020–0–BR–14];
174. Mexico Patent Application No.
MX/a/2022/010157 effective filing date
of February 26, 2021, entitled ‘‘HLA
Class II-Restricted T Cell Receptors
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
Against RAS with G12V Mutation’’
[HHS Ref. No. E–088–2020–0–MX–15];
175. New Zealand Patent Application
No. 791348 effective filing date of
February 26, 2021, entitled ‘‘HLA Class
II-Restricted T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–088–2020–0–NZ–16];
176. United States Provisional Patent
Application No. 63/050,931 filed July
13, 2020, entitled ‘‘HLA Class IIRestricted DRB T Cell Receptors Against
RAS with G12D Mutation’’ [HHS Ref.
No. E–165–2020–0–US–01];
177. PCT Patent Application No. PCT/
US2021/041375 filed July 13, 2021,
entitled ‘‘HLA Class II-Restricted DRB T
Cell Receptors Against RAS with G12D
Mutation’’ [HHS Ref. No. E–165–2020–
0–PCT–02];
178. United States Provisional Patent
Application No. 63/052,502 filed July
16, 2020, entitled ‘‘HLA Class IIRestricted DRB1*01:01 T Cell Receptors
Against RAS with G12V Mutation’’
[HHS Ref. No. E–172–2020–0–US–01];
179. PCT Patent Application No. PCT/
US2021/041737 filed July 15, 2021,
entitled ‘‘HLA Class II-Restricted
DRB1*01:01 T Cell Receptors Against
RAS with G12V Mutation’’ [HHS Ref.
No. E–172–2020–0–PCT–02];
180. United States Provisional Patent
Application No. 63/086,674 filed
October 2, 2020, entitled ‘‘HLA Class IIRestricted DQ T Cell Receptors Against
RAS with G13D Mutation’’ [HHS Ref.
No. E–189–2020–0–US–01];
181. PCT Patent Application No. PCT/
US2021/053060 filed October 1, 2021,
entitled ‘‘HLA Class II-Restricted DQ T
Cell Receptors Against RAS with G13D
Mutation’’ [HHS Ref. No. E–189–2020–
1–PCT–01];
182. Taiwanese Patent Application
No. 110136658 filed October 1, 2021,
entitled ‘‘HLA Class II-Restricted DQ T
Cell Receptors Against RAS with G13D
Mutation’’ [HHS Ref. No. E–189–2020–
1–TW–02]; and
183. United States Provisional Patent
Application No. 63/284,884 filed
December 1, 2021, entitled ‘‘HLA–A3Restricted T Cell Receptors Against RAS
with G12V Mutation’’ [HHS Ref. No. E–
219–2021–0–US–01].
Group B
1. United States Provisional Patent
Application No. 62/565,383 filed
September 29, 2017, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–0–US–
01];
2. PCT Patent Application No. PCT/
US2018/051285 filed September 17,
2018, entitled ‘‘T Cell Receptors
Recognizing Mutated P53’’ [HHS
Reference No. E–237–2017–2–PCT–01];
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
80561
3. Australian Patent Application No.
2018342246 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–
AU–02];
4. Brazilian Patent Application No.
BR112020006012–7 effective filing date
of September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–BR–
03];
5. Canadian Patent Application No.
3,077,024 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–
CA–04];
6. Chinese Patent Application No.
201880074539.8 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–
CN–05];
7. Costa Rican Application No. 2020–
0170 effective filing date of September
17, 2018, entitled ‘‘T Cell Receptors
Recognizing Mutated P53’’ [HHS
Reference No. E–237–2017–2–CR–06];
8. Eurasian Application No.
202090757 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–EA–
07];
9. European Patent Application No.
18780006.5 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–EP–
08];
10. Israeli Patent Application No.
273515 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–IL–
09];
11. Indian Patent Application No.
202047013911 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–IN–
10];
12. Japanese Patent Application No.
2020–517556 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–JP–
11];
13. Korean Patent Application No.
2020–7012344 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–KR–
12];
14. Mexican Application No. MX/a/
2020/003504 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
80562
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
[HHS Reference No. E–237–2017–2–
MX–13];
15. New Zealand Patent Application
No. 763023 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–
NZ–14];
16. Singapore Patent Application No.
11202002636P effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–SG–
15];
17. United States Patent Application
No. 16/651,242 effective filing date of
September 17, 2018, entitled ‘‘T Cell
Receptors Recognizing Mutated P53’’
[HHS Reference No. E–237–2017–2–US–
16];
18. Hong Kong Patent Application No.
62020021272.3 filed November 30,
2020, entitled ‘‘T Cell Receptors
Recognizing Mutated P53’’ [HHS
Reference No. E–237–2017–2–HK–17];
19. Brazilian Patent Application No.
BR122021018454–2 filed September 16,
2021, entitled ‘‘T Cell Receptors
Recognizing Mutated P53’’ [HHS
Reference No. E–237–2017–2–BR–18];
20. United States Provisional Patent
Application No. 62/867,619 filed June
27, 2019, entitled ‘‘T Cell Receptors
Recognizing R175H or Y220C Mutation
in P53’’ [HHS Reference No. E–135–
2019–0–US–01];
21. PCT Patent Application No. PCT/
US2020/039785, filed June 26, 2020,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–
PCT–02];
22. Taiwanese Patent Application No.
109121744 filed June 26, 2020, entitled
‘‘T Cell Receptors Recognizing R175H or
Y220C Mutation in P53’’ [HHS
Reference No. E–135–2019–0–TW–03];
23. Australian Patent Application No.
2020308004 filed January 6, 2022,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–
AU–04];
24. Brazilian Patent Application No.
BR112021026408–6 filed December 24,
2021, entitled ‘‘T Cell Receptors
Recognizing R175H or Y220C Mutation
in P53’’ [HHS Reference No. E–135–
2019–0–BR–05];
25. Canadian Patent Application No.
3,144,070 filed December 16, 2021,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–
CA–06];
26. Chinese Patent Application No.
202080047882.0 filed December 27,
2021, entitled ‘‘T Cell Receptors
Recognizing R175H or Y220C Mutation
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
in P53’’ [HHS Reference No. E–135–
2019–0–CN–07];
27. European Patent Application No.
20742583.6 filed January 27, 2022,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–EP–
08];
28. Indian Patent Application No.
202247003029 filed January 19, 2022,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–IN–
09];
29. Japanese Patent Application No.
2021–576970 filed December 24, 2021,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–JP–
10];
30. Mexican Patent Application No.
MX/a/2021/015877 filed December 16,
2021, entitled ‘‘T Cell Receptors
Recognizing R175H or Y220C Mutation
in P53’’ [HHS Reference No. E–135–
2019–0–MX–11];
31. Russian Patent Application No.
2022101295 filed January 20, 2022,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–
RU–12];
32. Singapore Patent Application No.
11202113949V filed December 15, 2021,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–SG–
13];
33. South African Patent Application
No. 2022/00598 filed January 12, 2022,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–
ZA–14];
34. Korean Patent Application No.
2022–7002872 filed January 26, 2022,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–KR–
15];
35. United States Patent Application
No. 17/620,942 filed December 20, 2021,
entitled ‘‘T Cell Receptors Recognizing
R175H or Y220C Mutation in P53’’
[HHS Reference No. E–135–2019–0–US–
16];
36. United States Provisional Patent
Application No. 63/074,747 filed
September 4, 2020, entitled ‘‘T Cell
Receptors Recognizing R273C or Y220C
Mutation in P53’’ [HHS Reference No.
E–173–2020–0–US–01];
37. PCT Patent Application No. PCT/
US2021/048786 filed September 2,
2021, entitled ‘‘T Cell Receptors
Recognizing R273C or Y220C Mutation
in P53’’ [HHS Reference No. E–173–
2020–0–PCT–02];
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
38. Taiwanese Patent Application No.
110132552 filed September 2, 2021,
entitled ‘‘T Cell Receptors Recognizing
R273C or Y220C Mutation in P53’’ [HHS
Reference No. E–173–2020–0–TW–03];
39. United States Provisional Patent
Application No. 63/185,805 filed May 7,
2021, entitled ‘‘T Cell Receptors
Recognizing C135Y, R175H or M237I
Mutation in P53’’ [HHS Reference No.
E–101–2021–0–US–01]; and
40. PCT Patent Application No. PCT/
US2022/028066 filed May 6, 2022,
entitled ‘‘T Cell Receptors Recognizing
C135Y, R175H or M237I Mutation in
P53’’ [HHS Reference No. E–101–2021–
0–PCT–02].
Group C
1. United States Provisional Patent
Application No. 62/004,335 filed May
29, 2014, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–US–
01];
2. PCT Patent Application No. PCT/
US2015/033129 filed May 29, 2015,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–PCT–02];
3. Australian Patent No. 2015266818
issued January 16, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–AU–03];
4. Brazilian Patent Application No.
BR112016027805–4 effective filing date
of May 29, 2015, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–BR–
04];
5. Canadian Patent Application No.
2,950,192 effective filing date of May 29,
2015, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–
CA–05];
6. Chinese Patent No.
ZL201580031789.X issued May 4, 2021,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–CN–06];
7. European Patent No. 3149031
issued December 18, 2019, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–EP–07];
a. Validated in the following
jurisdictions: AL, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LT, LU, LV, MK, MT, NL,
NO, PL, PT, RO, SE, SI, SK, SM and TR.
8. Israeli Patent No. 248797 issued
September 1, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–IL–08];
9. Japanese Patent No. 6742991 issued
August 19, 2020, entitled ‘‘Anti-Human
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–JP–
09];
10. Korean Patent Application No.
2016–7033189 effective filing date of
May 29, 2015, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–KR–
10];
11. Mexican Patent No. 375379 issued
September 25, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–MX–11];
12. Saudi Arabian Patent No. 7456
issued January 5, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–SA–12];
13. United States Patent No.
10,174,098 issued January 8, 2019,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–13];
14. Hong Kong Patent No. HK1236203
issued January 8, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–HK–14];
15. United States Patent No.
10,870,687 issued December 22, 2020,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–15];
16. European Patent Application No.
19217074.4 filed December 17, 2019,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–EP–16];
17. Australian Patent No. 2019283892
issued May 13, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–AU–17];
18. Japanese Patent No. 6997267
issued December 20, 2021, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–JP–53];
19. Saudi Arabian Patent Application
No. 520412601 filed August 10, 2020,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–SA–54];
20. Hong Kong Patent Application No.
42020020661.3 filed November 24,
2020, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–
HK–55];
21. Mexican Patent Application No.
MX/a/2020/010035 filed September 24,
2020, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–
MX–56];
22. United States Patent No.
11,434,272 issued September 6, 2020,
entitled ‘‘Anti-Human Papillomavirus
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–57];
23. Australian Patent Application No.
2021202227 filed April 13, 2021,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–AU–58];
24. Chinese Patent Application No.
20210399056.9 filed April 14, 2021,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–CN–59];
25. Israeli Patent No. 282518 issued
July 2, 2022, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–IL–
60];
26. Hong Kong Patent Application No.
42022046605.6 filed January 19, 2022,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–HK–62];
27. Japanese Patent Application No.
2021–203953 filed December 16, 2021,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–JP–63];
28. Israeli Patent Application No.
290655 filed February 16, 2022, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–IL–64];
29. United States Patent Application
No. 17/816,496 filed August 1, 2022,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–65]; and
30. Korean Patent Application No.
2022–7032043 filed September 15, 2022,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–KR–66].
Group D
1. United States Provisional Patent
Application No. 61/535,086 filed
September 15, 2011, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–US–01];
2. PCT Patent Application No. PCT/
US2012/051623 filed September 11,
2012, entitled ‘‘T Cell Receptors
Recognizing HLA–A1– or HLA–CW7–
Restricted MAGE’’ [HHS Reference No.
E–266–2011–0–PCT–02];
3. Australian Patent No. 2012309830
issued July 13, 2017, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–AU–03];
4. Canadian Patent No. 2,848,209
issued June 1, 2021, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–CA–04];
5. European Patent No. 2755997
issued July 4, 2018, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
80563
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–EP–05];
a. Validated in the following
jurisdictions: AT, BE, CH, CZ, DE, ES,
FR, GB, GR, IE, IT, NL, NO, PL, PT, SE,
SI, SK and TR.
6. Japanese Patent No. 6415322 issued
October 12, 2018, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–JP–06];
7. United States Patent Application
No. 14/344,354 filed March 14, 2014,
entitled ‘‘T Cell Receptors Recognizing
HLA–A1– or HLA–CW7–Restricted
MAGE’’ [HHS Reference No. E–266–
2011–0–US–07];
8. Chinese Patent Application No.
201280055972.X filed May 14, 2014,
entitled ‘‘T Cell Receptors Recognizing
HLA–A1– or HLA–CW7–Restricted
MAGE’’ [HHS Reference No. E–266–
2011–0–CN–08];
9. Israeli Patent No. 231323 issued
November 30, 2019, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–IL–09];
10. Australian Patent No. 2017204103
issued June 20, 2019, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–AU–10];
11. European Patent No. 3392270
issued August 26, 2020, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–EP–11];
a. Validated in: AT, BE, CH, CZ, DE,
ES, FR, GB, GR, IE, IT, NL, NO, PL, PT,
SE, SI, SK and TR.
12. Chinese Patent Application No.
201811170958.X filed October 8, 2018,
entitled ‘‘T Cell Receptors Recognizing
HLA–A1– or HLA–CW7–Restricted
MAGE’’ [HHS Reference No. E–266–
2011–0–CN–14];
13. United States Patent No.
11,306,131 issued April 19, 2022,
entitled ‘‘T Cell Receptors Recognizing
HLA–A1– or HLA–CW7–Restricted
MAGE’’ [HHS Reference No. E–266–
2011–0–US–32];
14. Japanese Patent No. 6855426
issued March 19, 2021, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–JP–33];
15. Hong Kong Patent No. HK1262936
issued June 4, 2021, entitled ‘‘T Cell
Receptors Recognizing HLA–A1– or
HLA–CW7–Restricted MAGE’’ [HHS
Reference No. E–266–2011–0–HK–34];
16. Hong Kong Patent Application No.
19129278.8 filed September 6, 2019,
entitled ‘‘T Cell Receptors Recognizing
HLA–A1– or HLA–CW7–Restricted
MAGE’’ [HHS Reference No. E–266–
2011–0–HK–35];
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
80564
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
17. Israeli Patent No. 268157 issued
July 30, 2021, entitled ‘‘T Cell Receptors
Recognizing HLA–A1– or HLA–CW7–
Restricted MAGE’’ [HHS Reference No.
E–266–2011–0–IL–36];
18. European Patent Application No.
20192082.4 filed July 18, 2019, entitled
‘‘T Cell Receptors Recognizing HLA–
A1– or HLA–CW7–Restricted MAGE’’
[HHS Reference No. E–266–2011–0–EP–
37];
19. Israeli Patent No. 268157 issued
June 2, 2022, entitled ‘‘T Cell Receptors
Recognizing HLA–A1– or HLA–CW7–
Restricted MAGE’’ [HHS Reference No.
E–266–2011–0–IL–57];
20. Japanese Patent Application No.
2021–043845 filed March 17, 2021,
entitled ‘‘T Cell Receptors Recognizing
HLA–A1– or HLA–CW7–Restricted
MAGE’’ [HHS Reference No. E–266–
2011–0–JP–58];
21. Canadian Patent Application No.
3,114,877 filed April 13, 2021, entitled
‘‘T Cell Receptors Recognizing HLA–
A1– or HLA–CW7–Restricted MAGE’’
[HHS Reference No. E–266–2011–0–
CA–59];
22. Israeli Patent Application No.
290105 filed January 25, 2022, entitled
‘‘T Cell Receptors Recognizing HLA–
A1– or HLA–CW7–Restricted MAGE’’
[HHS Reference No. E–266–2011–0–IL–
60];
23. United States Patent Application
No. 17/691,569 filed March 10, 2022,
entitled ‘‘T Cell Receptors Recognizing
HLA–A1– or HLA–CW7–Restricted
MAGE’’ [HHS Reference No. E–266–
2011–0–US–61];
24. United States Provisional Patent
Application No. 61/701,056 filed
September 14, 2012, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–US–01];
25. PCT Patent Application No. PCT/
US2013/059608 filed September 13,
2013, entitled ‘‘T Cell Receptors
Recognizing MHC Class II–Restricted
Mage–A3’’ [HHS Reference No. E–230–
2012–0–PCT–02];
26. Australian Patent No. 2013315391
issued September 21, 2017, entitled ‘‘T
Cell Receptors Recognizing MHC Class
II–Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–AU–03];
27. Canadian Patent Application No.
2,884,743 filed September 13, 2013,
entitled ‘‘T Cell Receptors Recognizing
MHC Class II–Restricted Mage–A3’’
[HHS Reference No. E–230–2012–0–
CA–04];
28. Chinese Patent No.
ZL201380059102.4 issued September
24, 2021, entitled ‘‘T Cell Receptors
Recognizing MHC Class II–Restricted
Mage–A3’’ [HHS Reference No. E–230–
2012–0–CN–05];
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
29. European Patent No. 2895509
issued December 4, 2019, entitled ‘‘T
Cell Receptors Recognizing MHC Class
II–Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–EP–06];
a. Validated in the following
jurisdictions: AL, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LI, LT, LU, LV, MK, MT,
NL, NO, PL, PT, RO, RS, SE, SI, SK, SM
and TR.
30. Israeli Patent No. 237560 issued
September 1, 2020, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–IL–07];
31. Japanese Patent No. 6461796
issued January 11, 2019, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–JP–08];
32. Korean Patent No. 2165350 issued
October 6, 2020, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–KR–09];
33. Mexican Patent No. 367279 issued
August 13, 2019, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–MX–10];
34. United States Patent No. 9,879,065
issued January 30, 2018, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–US–11];
35. Australian Patent No. 2017219019
issued August 22, 2019, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–AU–12];
36. United States Patent No.
10,611,815 issued April 7, 2020, entitled
‘‘T Cell Receptors Recognizing MHC
Class II–Restricted Mage–A3’’ [HHS
Reference No. E–230–2012–0–US–13];
37. Japanese Patent No. 6728326
issued July 3, 2020, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–JP–14];
38. Australian Patent No. 2019213329
issued June 24, 2021, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–AU–15];
39. Mexican Patent Application No.
MX/a/2019/009641 filed August 13,
2019, entitled ‘‘T Cell Receptors
Recognizing MHC Class II–Restricted
Mage–A3’’ [HHS Reference No. E–230–
2012–0–MX–16];
40. European Patent No. 3636665
issued June 29, 2022, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–EP–17];
a. Validated in: BE, DK, FR, DE, IT,
NL, NO, ES, SE, CH and GB.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
41. United States Patent Application
No. 16/812,845 filed March 9, 2020,
entitled ‘‘T Cell Receptors Recognizing
MHC Class II–Restricted Mage–A3’’
[HHS Reference No. E–230–2012–0–US–
58];
42. Israeli Patent No. 274003 issued
February 1, 2022, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–IL–59];
43. Japanese Patent Application No.
2020–114090 filed July 1, 2020, entitled
‘‘T Cell Receptors Recognizing MHC
Class II–Restricted Mage–A3’’ [HHS
Reference No. E–230–2012–0–JP–60];
44. Hong Kong Patent Application No.
42020016865.6 filed September 25,
2020, entitled ‘‘T Cell Receptors
Recognizing MHC Class II–Restricted
Mage–A3’’ [HHS Reference No. E–230–
2012–0–HK–61];
45. Korean Patent No. 2303166 issued
September 10, 2021, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–KR–62];
46. Australian Patent Application No.
2021203746 filed June 7, 2021, entitled
‘‘T Cell Receptors Recognizing MHC
Class II–Restricted Mage–A3’’ [HHS
Reference No. E–230–2012–0–AU–63];
47. Japanese Patent Application No.
2021–124003 filed July 29, 2021,
entitled ‘‘T Cell Receptors Recognizing
MHC Class II–Restricted Mage–A3’’
[HHS Reference No. E–230–2012–0–JP–
64];
48. Chinese Patent Application No.
202111028896.0 filed September 1,
2021, entitled ‘‘T Cell Receptors
Recognizing MHC Class II–Restricted
Mage–A3’’ [HHS Reference No. E–230–
2012–0–CN–65];
49. Korean Patent No. 2370307 issued
February 28, 2022, entitled ‘‘T Cell
Receptors Recognizing MHC Class II–
Restricted Mage–A3’’ [HHS Reference
No. E–230–2012–0–KR–66];
50. Israeli Patent Application No.
286786 filed September 29, 2021,
entitled ‘‘T Cell Receptors Recognizing
MHC Class II–Restricted Mage–A3’’
[HHS Reference No. E–230–2012–0–IL–
67];
51. Hong Kong Patent Application No.
42022051280.0 filed April 7, 2022,
entitled ‘‘T Cell Receptors Recognizing
MHC Class II–Restricted Mage–A3’’
[HHS Reference No. E–230–2012–0–
HK–68];
52. Korean Patent Application No.
10–2022–7006700 filed February 25,
2022, entitled ‘‘T Cell Receptors
Recognizing MHC Class II–Restricted
Mage–A3’’ [HHS Reference No. E–230–
2012–0–KR–69];
53. European Patent Application No.
22174521.9 filed May 20, 2022, entitled
E:\FR\FM\30DEN1.SGM
30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
‘‘T Cell Receptors Recognizing MHC
Class II–Restricted Mage–A3’’ [HHS
Reference No. E–230–2012–0–EP–70];
and
54. United States Patent Application
No. 17/936,006 filed September 28,
2022, entitled ‘‘T Cell Receptors
Recognizing MHC Class II–Restricted
Mage–A3’’ [HHS Reference No. E–230–
2012–0–US–82].
(and U.S. and foreign patent
applications claiming priority to the
aforementioned applications)
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the
following:
‘‘Development, manufacture and
commercialization of allogeneic Natural
Killer (NK) cell therapy products
engineered to express a therapeutic T
cell receptor claimed in the Licensed
Patent Rights for the treatment or
prevention of cancer in humans.
Specifically excluded from this field
of use are Natural Killer T (NKT) cell
therapy products engineered via viral
and non-viral means for the treatment of
human cancers, wherein the NKT cell
therapy product contains at least 50%
NKT cells.’’
Intellectual Property Group A is
primarily directed to isolated T cell
receptors (TCRs) reactive to mutated
Kirsten rat sarcoma viral oncogene
homolog (KRAS), within the context of
several human leukocyte antigens
(HLAs). Mutated KRAS, which plays a
well-defined driver role in oncogenesis,
is expressed by a variety of human
cancers, including pancreatic, lung,
endometrial, ovarian and prostate. Due
to its restricted expression in
precancerous and cancerous cells, this
antigen may be targeted on mutant
KRAS-expressing tumors with minimal
normal tissue toxicity.
Intellectual Property Group B is
primarily directed to isolated TCRs
reactive to mutated tumor protein 53
(TP53 or P53), within the context of
several HLAs. P53 is the archetypal
tumor suppressor gene and the most
frequently mutated gene in cancer.
Contemporary estimates suggest that
>50% of all tumors carry mutations in
P53. Because of its prevalence in cancer
and its restricted expression to
precancerous and cancerous cells, this
antigen may be targeted on mutant P53expressing tumors with minimal normal
tissue toxicity.
Intellectual Property Group C is
primarily directed to isolated TCRs
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
reactive to the E7 oncoprotein of Human
Papilloma Virus (HPV) type 16, within
the context of HLA–A*02. E7
oncoprotein drives malignant
transformation in HPV-infected cells.
Due to its specific and constitutive
expression in cancer cells, this antigen
may be targeted in HPV-positive
malignancies, such as cervical
carcinoma and oropharyngeal
carcinoma, with minimal normal tissue
toxicity.
Intellectual Property Group D is
primarily directed to isolated TCRs
reactive to Melanoma-associated
antigens 3, 6 and 12 (MAGE–A3/A6/
A12), within the context of multiple
HLAs. There are twelve MAGE–A
superfamily antigens designated A1–
A12. These antigens are among the most
commonly expressed cancer testis
antigens in a variety of tumors and are
associated with poor disease prognosis.
They are not expressed on normal cells
other than non-MHC expressing germ
cells of the testis, which do not generate
an immune response. Thus, these
antigens may be targeted on MAGE–Aexpressing tumors with minimal normal
tissue toxicity.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: December 23, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2022–28404 Filed 12–29–22; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
80565
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Aging.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Aging.
Date: September 19–20, 2023.
Closed: September 19, 2023, 3:00 p.m. to
5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Open: September 20, 2023, 10:00 a.m. to
2:00 p.m.
Agenda: Call to order and report from the
Director; Discussion of future meeting dates;
Consideration of minutes of last meeting;
Reports from Task Force on Minority Aging
Research, Working Group on Program;
Council Speaker; Program Highlights.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Closed: September 20, 2023, 2:00 p.m. to
2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kenneth Santora, Ph.D.,
Director, Office of Extramural Activities,
National Institute on Aging, National
Institutes of Health, Gateway Building, 7201
Wisconsin Avenue, Bethesda, MD 20814,
(301) 496–9322, ksantora@nih.gov.
Information is also available on the
Institute’s/Center’s home page:
www.nia.nih.gov/about/naca, where an
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 87, Number 250 (Friday, December 30, 2022)]
[Notices]
[Pages 80556-80565]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-28404]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Development and
Commercialization of Natural Killer Cell Therapies for Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this notice to Replay Holdings
LLC (``Replay'') located in San Diego, California.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before January 17, 2023 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Suna Gulay French, Technology Transfer Manager,
Telephone: (240) 276-7424; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
Group A
1. United States Provisional Patent Application No. 62/084,654
filed November 26, 2014, entitled ``Anti-Mutated KRAS T Cell
Receptors'' [HHS Reference No. E-028-2015-0-US-01];
2. PCT Patent Application No. PCT/US2015/062269 filed November 24,
2015, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-PCT-01];
3. Australian Patent No. 2015353720 issued June 11, 2020, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
AU-02];
4. Canadian Patent Application No. 2,968,399 effective filing date
of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-028-2015-1-CA-03];
5. Chinese Patent No. ZL201580070673.7 issued November 16, 2021,
entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-
028-2015-1-CN-04];
6. European Patent No. 3223850 issued January 8, 2020, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
EP-05];
a. Validated in the following jurisdictions: AT, BE, CH, CZ, DE,
ES, FR, GB, GR, IE, IT, NL, NO, PL, PT, SE, SI, SK, TR;
7. Israeli Patent No. 252258 issued March 2, 2022, entitled ``Anti-
Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-IL-06];
8. Japanese Patent No. 6863893 issued April 5, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
JP-07];
9. Korean Patent Application No. 2017-7017289 effective filing date
of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-028-2015-1-KR-08];
10. Mexican Patent No. 384919 issued July 29, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
MX-09];
11. New Zealand Patent Application No. 732045 effective filing date
of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-028-2015-1-NZ-10];
12. Saudi Arabian Patent No. 7697 issued March 11, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
SA-11];
13. Singapore Patent Application No. 11201704155U effective filing
date of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell
Receptors'' [HHS Reference No. E-028-2015-1-SG-12];
14. United States Patent No. 11,207,394 issued December 28, 2021,
entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-
028-2015-1-US-13];
15. Hong Kong Patent No. 1243642 issued January 22, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
HK-14];
16. European Patent Application No. 20150279.6 filed January 3,
2020, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-EP-15];
17. Singapore Patent Application No. 10201913978R filed December
31, 2019, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS
Reference No. E-028-2015-1-SG-16];
18. Australian Patent Application No. 2020203465 filed May 26,
2020, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-AU-36];
19. Saudi Arabian Patent Application No. 520420365 filed October
15, 2020, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS
Reference No. E-028-2015-1-SA-37];
20. Hong Kong Patent Application No. 42020021375.9 effective filing
date of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell
Receptors'' [HHS Reference No. E-028-2015-1-HK-38];
21. Japanese Patent Application No. 2021-063092 filed April 1,
2021, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-JP-40];
22. Chinese Patent Application No. 202111263859.8 filed October 27,
2021, entitled ``Anti-Mutated KRAS T Cell
[[Page 80557]]
Receptors'' [HHS Reference No. E-028-2015-1-CN-41];
23. United States Patent Application No. 17/535,318 filed November
24, 2021, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS
Reference No. E-028-2015-1-US-42];
24. Hong Kong Patent Application No. 42022054674.1 filed June 27,
2022, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-HK-43];
25. United States Provisional Patent Application No. 62/171,321
filed June 5, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-180-2015-0-US-01];
26. United States Provisional Patent Application No. 62/218,688
filed September 15, 2015, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-US-01];
27. PCT Patent Application No. PCT/US2016/050875 filed September 9,
2016, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-PCT-02];
28. Australian Patent No. 2016323017 issued February 25, 2021,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-AU-03];
29. Canadian Patent Application No. 2,998,869 effective filing date
of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-CW8
Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-CA-04];
30. Chinese Patent No. ZL201680058891.3 issued October 8, 2021,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-CN-05];
31. European Patent No. 3350213 issued March 31, 2021, entitled ``T
Cell Receptors Recognizing HLA-CW8 Restricted Mutated KRAS'' [HHS
Reference No. E-265-2015-0-EP-06];
a. Validated in the following jurisdictions: BE, CH, DE, DK, ES,
FR, GB, IE, IT, NL, NO and SE.
32. Israeli Patent Application No. 257840 effective filing date of
September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-CW8
Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-IL-07];
33. Japanese Patent Application No. 2018-513423 effective filing
date of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-JP-08];
34. Korean Patent Application No. 2018-7010326, effective filing
date of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-KR-09];
35. Mexican Patent Application No. MX/a/2018/003062 effective
filing date of September 9, 2016, entitled ``T Cell Receptors
Recognizing HLA-CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-
2015-0-MX-10];
36. New Zealand Patent Application No. 740714 effective filing date
of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-CW8
Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-NZ-11];
37. Saudi Arabian Patent Application No. 518391109 effective filing
date of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-SA-12];
38. Singapore Patent No. 11201802069U issued March 31, 2022,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-SG-13];
39. United States Patent No. 10,556,940 issued February 11, 2020,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-US-14];
40. Hong Kong Patent No. HK1257902 issued December 24, 2021,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-HK-15];
41. United States Patent Application No. 16/739,310 filed January
10, 2020, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-US-16];
42. Singapore Patent Application No. 10201913868X filed December
30, 2019, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-SG-17];
43. Australian Patent No. 2021200833 issued August 18, 2022,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-AU-18];
44. European Patent Application No. 21162567.8 filed March 15,
2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-EP-19];
45. Saudi Arabian Patent Application No. 521421309 filed February
23, 2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-SA-20];
46. Chinese Patent Application No. 202111083392.9 filed September
15, 2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-CN-33];
47. New Zealand Patent Application No. 779633 filed September 2,
2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-NZ-34];
48. Australian Patent Application No. 2022209229 filed July 26,
2022, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-AU-35];
49. United States Provisional Patent Application No. 62/369,883
filed August 2, 2016, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS
Reference No. E-175-2016-0-US-01];
50. PCT Patent Application No. PCT/US2017/044615 filed July 31,
2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-PCT-02];
51. Australian Patent Application No. 2017306038 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-AU-03];
52. Canadian Patent Application No. 3,032,870 effective filing date
of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS
Reference No. E-175-2016-0-CA-04];
53. Chinese Patent Application No. 201780059356.4 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-CN-05];
54. European Patent No. 3494133 issued July 6, 2022, entitled
``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-EP-
06];
a. Validated in the following jurisdictions: AL, AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, HR, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM and TR.
55. Japanese Patent Application No. 2019-505220 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-JP-07];
56. United States Patent No. 10,611,816 issued April 7, 2020,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-08];
57. Israeli Patent Application No. 264425 effective filing date of
July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS
Reference No. E-175-2016-0-IL-09];
58. Korean Patent Application No. 2019-7005837 effective filing
date of July 31, 2017, entitled ``Anti-KRAS
[[Page 80558]]
G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-KR-10];
59. Singapore Patent Application No. 11201900654Q effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-SG-11];
60. Hong Kong Patent Application No. 19133082.8 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-HK-12];
61. Hong Kong Patent Application No. 19132196.7 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-HK-13];
62. Singapore Patent Application No. 10201913959W filed December
31, 2019, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-SG-14];
63. United States Patent No. 11,208,456 issued December 28, 2021,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-15];
64. United States Patent Application No. 17/345,390 filed June 11,
2021, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-US-16];
65. United States Patent Application No. 17/541,619 filed December
3, 2021, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-US-17];
66. Japanese Patent Application No. 2021-199878 filed December 9,
2021, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-JP-18];
67. European Patent Application No. 22182473.3 filed July 1, 2022,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-EP-19];
68. United States Provisional Patent Application No. 62/560,930
filed September 20, 2017, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-US-01];
69. PCT Patent Application No. PCT/US2018/051641 filed September
19, 2018, entitled ``HLA Class II-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-181-2017-0-PCT-02];
70. Argentina Patent Application No. P180102695 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-AR-03];
71. Taiwanese Patent Application No. 107133221 filed September 20,
2018, entitled ``HLA Class II-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-181-2017-0-TW-05];
72. United States Patent No. 11,306,132 issued April 19, 2022,
entitled ``HLA Class II-Restricted T Cell Receptors Against Mutated
RAS'' [HHS Reference No. E-181-2017-0-US-06];
73. Australian Patent Application No. 2018335274 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-AU-07];
74. Brazilian Patent Application No. BR112020005469-0 effective
filing date of September 19, 2018, entitled ``HLA Class II-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-
BR-08];
75. Canadian Patent Application No. 3,076,339 effective filing date
of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-CA-09];
76. Chinese Patent Application No. 201880060535.4 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-CN-10];
77. Costa Rican Patent Application No. 2020-0150 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-CR-11];
78. Eurasian Patent Application No. 202090652 effective filing date
of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-EA-12];
79. European Patent Application No. 18792591.2 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-EP-13];
80. Israeli Patent Application No. 273254 effective filing date of
September 19, 2018, entitled ``HLA Class II-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-181-2017-0-IL-14];
81. Indian Patent Application No. 202047011647 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-IN-15];
82. Japanese Patent Application No. 2020-516422 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-JP-16];
83. Korean Patent Application No. 2020-7011112 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-KR-17];
84. Mexican Patent Application No. MX/a/2020/003117 effective
filing date of September 19, 2018, entitled ``HLA Class II-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-
MX-18];
85. New Zealand Patent Application No. 762831 effective filing date
of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-NZ-19];
86. Singapore Patent Application No. 11202002425P effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-SG-20];
87. Hong Kong Patent Application No. 62020019700.7 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-HK-21];
88. Brazilian Patent Application No. BR122021018418-6 filed
September 16, 2021, entitled ``HLA Class II-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-181-2017-0-BR-22];
89. United States Patent Application No. 17/692,787 filed March 11,
2022, entitled ``HLA Class II-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-181-2017-0-US-23];
90. United States Provisional Patent Application No. 62/594,244
filed December 4, 2017, entitled ``HLA Class I-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-US-01];
91. PCT Patent Application No. PCT/US2018/063581 filed December 3,
2018, entitled ``HLA Class I-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-239-2017-0-PCT-02];
92. Australian Patent Application No. 2018378200 effective filing
date of December 3, 2018, entitled ``HLA Class I-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-AU-03];
93. Brazilian Patent Application No. BR112020011111-2 effective
filing date of December 3, 2018, entitled ``HLA Class I-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-
BR-04];
94. Canadian Application No. 3,084,246 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-CA-05];
[[Page 80559]]
95. Chinese Application No. 201880087270.7 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-CN-06];
96. Costa Rican Application No. 2020-0287 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-CR-07];
97. Eurasian Application No. 202091335 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-EA-08];
98. European Application No. 18830062.8 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-EP-09];
99. Israeli Application No. 275031 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-IL-10];
100. Indian Application No. 202047026991 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-IN-11];
101. Japanese Application No. 2020-530325 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-JP-12];
102. Korean Application No. 2020-7019185 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-KR-13];
103. Mexican Application No. MX/a/2020/005765 effective filing date
of December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-MX-14];
104. New Zealand Application No. 765440 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-NZ-15];
105. Singapore Application No. 11202005236Q effective filing date
of December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-SG-16];
106. United States Patent Application No. 16/769,144 effective
filing date of December 3, 2018, entitled ``HLA Class I-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-
US-17];
107. Hong Kong Patent Application No. 62021026617.2 effective
filing date of December 3, 2018, entitled ``HLA Class I-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-
HK-18];
108. Brazilian Patent Application No. BR122021024382-4 filed
December 2, 2021, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-BR-19];
109. United States Patent Application No. 17/931,391 filed
September 12, 2022, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-US-20];
110. United States Provisional Patent Application No. 62/795,203
filed January 22, 2019, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-US-01];
111. Taiwanese Patent Application No. 109102511 filed January 22,
2020, entitled ``HLA Class II-Restricted T Cell Receptors Against RAS
with G12R Mutation'' [HHS Reference No. E-029-2019-0-TW-02];
112. PCT Patent Application No. PCT/US2020/014382 filed January 21,
2020, entitled ``HLA Class II-Restricted T Cell Receptors Against RAS
with G12R Mutation'' [HHS Reference No. E-029-2019-0-PCT-03];
113. Australian Patent Application No. 2020211922 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-AU-04];
114. Canadian Patent Application No. 3,127,096 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-CA-05];
115. Chinese Patent Application No. 202080010373.0 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-CN-06];
116. European Patent Application No. 20705599.7 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-EP-07];
117. Japanese Patent Application No. 2021-542206 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-JP-08];
118. Korean Patent Application No. 2021-7026169 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-KR-09];
119. United States Patent Application No. 17/424,591 effective
filing date of January 21, 2020, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-
029-2019-0-US-10];
120. Hong Kong Patent Application No. 62022048432.8 effective
filing date of January 21, 2020, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-
029-2019-0-HK-11];
121. Hong Kong Patent Application No. 62022047561.5 effective
filing date of January 21, 2020, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-
029-2019-0-HK-12];
122. United States Provisional Patent Application No. 62/975,544
filed February 12, 2020, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
US-01];
123. PCT Patent Application No. PCT/US2021/017794 filed February
12, 2021, entitled ``HLA Class I-Restricted T Cell Receptors Against
RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-PCT-02];
124. Taiwanese Patent Application No. 110105194 filed February 12,
2021, entitled ``HLA Class I-Restricted T Cell Receptors Against RAS
with G12D Mutation'' [HHS Ref. No. E-031-2020-0-TW-03];
125. Australian Patent Application No. 2021221138 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
AU-04];
126. Canadian Patent Application No. 3,168,015 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CA-05];
127. Chinese Patent Application No. 202180014038.2 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CN-06];
128. European Patent Application No. 21710730.9 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
EP-07];
129. Indian Patent Application No. 202247050250 effective filing
date of February 12, 2021, entitled ``HLA Class
[[Page 80560]]
I-Restricted T Cell Receptors Against RAS with G12D Mutation'' [HHS
Ref. No. E-031-2020-0-IN-08];
130. Japanese Patent Application No. 2022-548811 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
JP-09];
131. Korean Patent Application No. 2022-7031175 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
KR-10];
132. Singapore Patent Application No. 11202251837Y effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
SG-11];
133. United Kingdom Patent Application No. 2211733.7 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-GB-12];
134. United States Patent Application No. 17/799,163 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-US-13];
135. Brazilian Patent Application No. BR112022015888-2 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-BR-14];
136. Chilean Patent Application No. 02208-2022 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CL-15];
137. Colombian Patent Application No. NC2022/0012922 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-CO-16];
138. Israeli Patent Application No. 295252 effective filing date of
February 12, 2021, entitled ``HLA Class I-Restricted T Cell Receptors
Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-IL-18];
139. Mexican Patent Application No. MX/a/2022/009654 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-MX-19];
140. New Zealand Patent Application No. 790950 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
NZ-20];
141. South African Patent Application No. 2022/08853 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-ZA-21];
142. Cuban Patent Application No. 2022-0044 effective filing date
of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CU-22];
143. Russian Patent Application No. 2022124004 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
RU-23];
144. United States Provisional Patent Application No. 62/976,655
filed February 14, 2020, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-0-
US-01];
145. United States Provisional Patent Application No. 63/060,340
filed August 3, 2020, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-190-2020-0-
US-01];
146. PCT Patent Application No. PCT/US2021/017852 filed February
12, 2021, entitled ``HLA Class I-Restricted T Cell Receptors Against
RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-PCT-01];
147. Taiwanese Patent Application No. 110105193 filed February 12,
2021, entitled ``HLA Class I-Restricted T Cell Receptors Against RAS
with G12V Mutation'' [HHS Ref. No. E-074-2020-1-TW-02];
148. Australian Patent Application No. 2021220957 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
AU-03];
149. Canadian Patent Application No. 3,167,382 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
CA-04];
150. Chinese Patent Application No. 202180014281.4 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
CN-05];
151. European Patent Application No. 21710740.8 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
EP-06];
152. Indian Patent Application No. 202247050807 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
IN-07];
153. Japanese Patent Application No. 2022-549088 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
JP-08];
154. Korean Patent Application No. 2022-7031589 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
KR-09];
155. Singapore Patent Application No. 11202251947C effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
SG-10];
156. United Kingdom Patent Application No. 2211757.6 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-GB-11];
157. United States Patent Application No. 17/799,193 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-US-12];
158. Brazilian Patent Application No. BR112022015897-1 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-BR-13];
159. Mexican Patent Application No. MX/a/2022/009825 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-MX-14];
160. New Zealand Patent Application No. 791024 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
NZ-15];
161. United States Provisional Patent Application No. 62/981,856
filed February 26, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
US-01];
162. PCT Patent Application No. PCT/US2021/019775 filed February
26, 2021, entitled ``HLA Class II-Restricted T Cell Receptors Against
RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-PCT-02];
163. Taiwanese Patent Application No. 110106886 filed February 26,
2021,
[[Page 80561]]
entitled ``HLA Class II-Restricted T Cell Receptors Against RAS with
G12V Mutation'' [HHS Ref. No. E-088-2020-0-TW-03];
164. Australian Patent Application No. 2021225872 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
AU-04];
165. Canadian Patent Application No. 3,169,086 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
CA-05];
166. Chinese Patent Application No. 202180016761.4 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
CN-06];
167. European Patent Application No. 21712694.5 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
EP-07];
168. Indian Patent Application No. 202247052620 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
IN-08];
169. Korean Patent Application No. 2022-7033222 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
KR-10];
170. Singapore Patent Application No. 1120225235K effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
SG-11];
171. United Kingdom Patent Application No. 2212195.8 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-GB-12];
172. United States Patent Application No. 17/802,464 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-US-13];
173. Brazilian Patent Application No. BR112022016661-3 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-BR-14];
174. Mexico Patent Application No. MX/a/2022/010157 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-MX-15];
175. New Zealand Patent Application No. 791348 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
NZ-16];
176. United States Provisional Patent Application No. 63/050,931
filed July 13, 2020, entitled ``HLA Class II-Restricted DRB T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-165-2020-0-
US-01];
177. PCT Patent Application No. PCT/US2021/041375 filed July 13,
2021, entitled ``HLA Class II-Restricted DRB T Cell Receptors Against
RAS with G12D Mutation'' [HHS Ref. No. E-165-2020-0-PCT-02];
178. United States Provisional Patent Application No. 63/052,502
filed July 16, 2020, entitled ``HLA Class II-Restricted DRB1*01:01 T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-172-
2020-0-US-01];
179. PCT Patent Application No. PCT/US2021/041737 filed July 15,
2021, entitled ``HLA Class II-Restricted DRB1*01:01 T Cell Receptors
Against RAS with G12V Mutation'' [HHS Ref. No. E-172-2020-0-PCT-02];
180. United States Provisional Patent Application No. 63/086,674
filed October 2, 2020, entitled ``HLA Class II-Restricted DQ T Cell
Receptors Against RAS with G13D Mutation'' [HHS Ref. No. E-189-2020-0-
US-01];
181. PCT Patent Application No. PCT/US2021/053060 filed October 1,
2021, entitled ``HLA Class II-Restricted DQ T Cell Receptors Against
RAS with G13D Mutation'' [HHS Ref. No. E-189-2020-1-PCT-01];
182. Taiwanese Patent Application No. 110136658 filed October 1,
2021, entitled ``HLA Class II-Restricted DQ T Cell Receptors Against
RAS with G13D Mutation'' [HHS Ref. No. E-189-2020-1-TW-02]; and
183. United States Provisional Patent Application No. 63/284,884
filed December 1, 2021, entitled ``HLA-A3-Restricted T Cell Receptors
Against RAS with G12V Mutation'' [HHS Ref. No. E-219-2021-0-US-01].
Group B
1. United States Provisional Patent Application No. 62/565,383
filed September 29, 2017, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-0-US-01];
2. PCT Patent Application No. PCT/US2018/051285 filed September 17,
2018, entitled ``T Cell Receptors Recognizing Mutated P53'' [HHS
Reference No. E-237-2017-2-PCT-01];
3. Australian Patent Application No. 2018342246 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-AU-02];
4. Brazilian Patent Application No. BR112020006012-7 effective
filing date of September 17, 2018, entitled ``T Cell Receptors
Recognizing Mutated P53'' [HHS Reference No. E-237-2017-2-BR-03];
5. Canadian Patent Application No. 3,077,024 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-CA-04];
6. Chinese Patent Application No. 201880074539.8 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-CN-05];
7. Costa Rican Application No. 2020-0170 effective filing date of
September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-CR-06];
8. Eurasian Application No. 202090757 effective filing date of
September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-EA-07];
9. European Patent Application No. 18780006.5 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-EP-08];
10. Israeli Patent Application No. 273515 effective filing date of
September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-IL-09];
11. Indian Patent Application No. 202047013911 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-IN-10];
12. Japanese Patent Application No. 2020-517556 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-JP-11];
13. Korean Patent Application No. 2020-7012344 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-KR-12];
14. Mexican Application No. MX/a/2020/003504 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53''
[[Page 80562]]
[HHS Reference No. E-237-2017-2-MX-13];
15. New Zealand Patent Application No. 763023 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-NZ-14];
16. Singapore Patent Application No. 11202002636P effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-SG-15];
17. United States Patent Application No. 16/651,242 effective
filing date of September 17, 2018, entitled ``T Cell Receptors
Recognizing Mutated P53'' [HHS Reference No. E-237-2017-2-US-16];
18. Hong Kong Patent Application No. 62020021272.3 filed November
30, 2020, entitled ``T Cell Receptors Recognizing Mutated P53'' [HHS
Reference No. E-237-2017-2-HK-17];
19. Brazilian Patent Application No. BR122021018454-2 filed
September 16, 2021, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-BR-18];
20. United States Provisional Patent Application No. 62/867,619
filed June 27, 2019, entitled ``T Cell Receptors Recognizing R175H or
Y220C Mutation in P53'' [HHS Reference No. E-135-2019-0-US-01];
21. PCT Patent Application No. PCT/US2020/039785, filed June 26,
2020, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-PCT-02];
22. Taiwanese Patent Application No. 109121744 filed June 26, 2020,
entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation in
P53'' [HHS Reference No. E-135-2019-0-TW-03];
23. Australian Patent Application No. 2020308004 filed January 6,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-AU-04];
24. Brazilian Patent Application No. BR112021026408-6 filed
December 24, 2021, entitled ``T Cell Receptors Recognizing R175H or
Y220C Mutation in P53'' [HHS Reference No. E-135-2019-0-BR-05];
25. Canadian Patent Application No. 3,144,070 filed December 16,
2021, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-CA-06];
26. Chinese Patent Application No. 202080047882.0 filed December
27, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-CN-07];
27. European Patent Application No. 20742583.6 filed January 27,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-EP-08];
28. Indian Patent Application No. 202247003029 filed January 19,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-IN-09];
29. Japanese Patent Application No. 2021-576970 filed December 24,
2021, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-JP-10];
30. Mexican Patent Application No. MX/a/2021/015877 filed December
16, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-MX-11];
31. Russian Patent Application No. 2022101295 filed January 20,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-RU-12];
32. Singapore Patent Application No. 11202113949V filed December
15, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-SG-13];
33. South African Patent Application No. 2022/00598 filed January
12, 2022, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-ZA-14];
34. Korean Patent Application No. 2022-7002872 filed January 26,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-KR-15];
35. United States Patent Application No. 17/620,942 filed December
20, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-US-16];
36. United States Provisional Patent Application No. 63/074,747
filed September 4, 2020, entitled ``T Cell Receptors Recognizing R273C
or Y220C Mutation in P53'' [HHS Reference No. E-173-2020-0-US-01];
37. PCT Patent Application No. PCT/US2021/048786 filed September 2,
2021, entitled ``T Cell Receptors Recognizing R273C or Y220C Mutation
in P53'' [HHS Reference No. E-173-2020-0-PCT-02];
38. Taiwanese Patent Application No. 110132552 filed September 2,
2021, entitled ``T Cell Receptors Recognizing R273C or Y220C Mutation
in P53'' [HHS Reference No. E-173-2020-0-TW-03];
39. United States Provisional Patent Application No. 63/185,805
filed May 7, 2021, entitled ``T Cell Receptors Recognizing C135Y, R175H
or M237I Mutation in P53'' [HHS Reference No. E-101-2021-0-US-01]; and
40. PCT Patent Application No. PCT/US2022/028066 filed May 6, 2022,
entitled ``T Cell Receptors Recognizing C135Y, R175H or M237I Mutation
in P53'' [HHS Reference No. E-101-2021-0-PCT-02].
Group C
1. United States Provisional Patent Application No. 62/004,335
filed May 29, 2014, entitled ``Anti-Human Papillomavirus 16 E7 T Cell
Receptors'' [HHS Reference No. E-176-2014-0-US-01];
2. PCT Patent Application No. PCT/US2015/033129 filed May 29, 2015,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-PCT-02];
3. Australian Patent No. 2015266818 issued January 16, 2020,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-AU-03];
4. Brazilian Patent Application No. BR112016027805-4 effective
filing date of May 29, 2015, entitled ``Anti-Human Papillomavirus 16 E7
T Cell Receptors'' [HHS Reference No. E-176-2014-0-BR-04];
5. Canadian Patent Application No. 2,950,192 effective filing date
of May 29, 2015, entitled ``Anti-Human Papillomavirus 16 E7 T Cell
Receptors'' [HHS Reference No. E-176-2014-0-CA-05];
6. Chinese Patent No. ZL201580031789.X issued May 4, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-CN-06];
7. European Patent No. 3149031 issued December 18, 2019, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-EP-07];
a. Validated in the following jurisdictions: AL, AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM and TR.
8. Israeli Patent No. 248797 issued September 1, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-IL-08];
9. Japanese Patent No. 6742991 issued August 19, 2020, entitled
``Anti-Human
[[Page 80563]]
Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No. E-176-2014-
0-JP-09];
10. Korean Patent Application No. 2016-7033189 effective filing
date of May 29, 2015, entitled ``Anti-Human Papillomavirus 16 E7 T Cell
Receptors'' [HHS Reference No. E-176-2014-0-KR-10];
11. Mexican Patent No. 375379 issued September 25, 2020, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-MX-11];
12. Saudi Arabian Patent No. 7456 issued January 5, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-SA-12];
13. United States Patent No. 10,174,098 issued January 8, 2019,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-US-13];
14. Hong Kong Patent No. HK1236203 issued January 8, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-HK-14];
15. United States Patent No. 10,870,687 issued December 22, 2020,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-US-15];
16. European Patent Application No. 19217074.4 filed December 17,
2019, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-EP-16];
17. Australian Patent No. 2019283892 issued May 13, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-AU-17];
18. Japanese Patent No. 6997267 issued December 20, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-JP-53];
19. Saudi Arabian Patent Application No. 520412601 filed August 10,
2020, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-SA-54];
20. Hong Kong Patent Application No. 42020020661.3 filed November
24, 2020, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-HK-55];
21. Mexican Patent Application No. MX/a/2020/010035 filed September
24, 2020, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-MX-56];
22. United States Patent No. 11,434,272 issued September 6, 2020,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-US-57];
23. Australian Patent Application No. 2021202227 filed April 13,
2021, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-AU-58];
24. Chinese Patent Application No. 20210399056.9 filed April 14,
2021, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-CN-59];
25. Israeli Patent No. 282518 issued July 2, 2022, entitled ``Anti-
Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No. E-176-
2014-0-IL-60];
26. Hong Kong Patent Application No. 42022046605.6 filed January
19, 2022, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-HK-62];
27. Japanese Patent Application No. 2021-203953 filed December 16,
2021, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-JP-63];
28. Israeli Patent Application No. 290655 filed February 16, 2022,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-IL-64];
29. United States Patent Application No. 17/816,496 filed August 1,
2022, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-US-65]; and
30. Korean Patent Application No. 2022-7032043 filed September 15,
2022, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-KR-66].
Group D
1. United States Provisional Patent Application No. 61/535,086
filed September 15, 2011, entitled ``T Cell Receptors Recognizing HLA-
A1- or HLA-CW7-Restricted MAGE'' [HHS Reference No. E-266-2011-0-US-
01];
2. PCT Patent Application No. PCT/US2012/051623 filed September 11,
2012, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-PCT-02];
3. Australian Patent No. 2012309830 issued July 13, 2017, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-AU-03];
4. Canadian Patent No. 2,848,209 issued June 1, 2021, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-CA-04];
5. European Patent No. 2755997 issued July 4, 2018, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-EP-05];
a. Validated in the following jurisdictions: AT, BE, CH, CZ, DE,
ES, FR, GB, GR, IE, IT, NL, NO, PL, PT, SE, SI, SK and TR.
6. Japanese Patent No. 6415322 issued October 12, 2018, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-JP-06];
7. United States Patent Application No. 14/344,354 filed March 14,
2014, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-US-07];
8. Chinese Patent Application No. 201280055972.X filed May 14,
2014, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-CN-08];
9. Israeli Patent No. 231323 issued November 30, 2019, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-IL-09];
10. Australian Patent No. 2017204103 issued June 20, 2019, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-AU-10];
11. European Patent No. 3392270 issued August 26, 2020, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-EP-11];
a. Validated in: AT, BE, CH, CZ, DE, ES, FR, GB, GR, IE, IT, NL,
NO, PL, PT, SE, SI, SK and TR.
12. Chinese Patent Application No. 201811170958.X filed October 8,
2018, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-CN-14];
13. United States Patent No. 11,306,131 issued April 19, 2022,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-US-32];
14. Japanese Patent No. 6855426 issued March 19, 2021, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-JP-33];
15. Hong Kong Patent No. HK1262936 issued June 4, 2021, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-HK-34];
16. Hong Kong Patent Application No. 19129278.8 filed September 6,
2019, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-HK-35];
[[Page 80564]]
17. Israeli Patent No. 268157 issued July 30, 2021, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-IL-36];
18. European Patent Application No. 20192082.4 filed July 18, 2019,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-EP-37];
19. Israeli Patent No. 268157 issued June 2, 2022, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-IL-57];
20. Japanese Patent Application No. 2021-043845 filed March 17,
2021, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-JP-58];
21. Canadian Patent Application No. 3,114,877 filed April 13, 2021,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-CA-59];
22. Israeli Patent Application No. 290105 filed January 25, 2022,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-IL-60];
23. United States Patent Application No. 17/691,569 filed March 10,
2022, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-US-61];
24. United States Provisional Patent Application No. 61/701,056
filed September 14, 2012, entitled ``T Cell Receptors Recognizing MHC
Class II-Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-US-01];
25. PCT Patent Application No. PCT/US2013/059608 filed September
13, 2013, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-PCT-02];
26. Australian Patent No. 2013315391 issued September 21, 2017,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-AU-03];
27. Canadian Patent Application No. 2,884,743 filed September 13,
2013, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-CA-04];
28. Chinese Patent No. ZL201380059102.4 issued September 24, 2021,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-CN-05];
29. European Patent No. 2895509 issued December 4, 2019, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-EP-06];
a. Validated in the following jurisdictions: AL, AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU,
LV, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM and TR.
30. Israeli Patent No. 237560 issued September 1, 2020, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-IL-07];
31. Japanese Patent No. 6461796 issued January 11, 2019, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-JP-08];
32. Korean Patent No. 2165350 issued October 6, 2020, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-KR-09];
33. Mexican Patent No. 367279 issued August 13, 2019, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-MX-10];
34. United States Patent No. 9,879,065 issued January 30, 2018,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-US-11];
35. Australian Patent No. 2017219019 issued August 22, 2019,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-AU-12];
36. United States Patent No. 10,611,815 issued April 7, 2020,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-US-13];
37. Japanese Patent No. 6728326 issued July 3, 2020, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-JP-14];
38. Australian Patent No. 2019213329 issued June 24, 2021, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-AU-15];
39. Mexican Patent Application No. MX/a/2019/009641 filed August
13, 2019, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-MX-16];
40. European Patent No. 3636665 issued June 29, 2022, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-EP-17];
a. Validated in: BE, DK, FR, DE, IT, NL, NO, ES, SE, CH and GB.
41. United States Patent Application No. 16/812,845 filed March 9,
2020, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-US-58];
42. Israeli Patent No. 274003 issued February 1, 2022, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-IL-59];
43. Japanese Patent Application No. 2020-114090 filed July 1, 2020,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-JP-60];
44. Hong Kong Patent Application No. 42020016865.6 filed September
25, 2020, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-HK-61];
45. Korean Patent No. 2303166 issued September 10, 2021, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-KR-62];
46. Australian Patent Application No. 2021203746 filed June 7,
2021, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-AU-63];
47. Japanese Patent Application No. 2021-124003 filed July 29,
2021, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-JP-64];
48. Chinese Patent Application No. 202111028896.0 filed September
1, 2021, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-CN-65];
49. Korean Patent No. 2370307 issued February 28, 2022, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-KR-66];
50. Israeli Patent Application No. 286786 filed September 29, 2021,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-IL-67];
51. Hong Kong Patent Application No. 42022051280.0 filed April 7,
2022, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-HK-68];
52. Korean Patent Application No. 10-2022-7006700 filed February
25, 2022, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-KR-69];
53. European Patent Application No. 22174521.9 filed May 20, 2022,
entitled
[[Page 80565]]
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-EP-70]; and
54. United States Patent Application No. 17/936,006 filed September
28, 2022, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-US-82].
(and U.S. and foreign patent applications claiming priority to the
aforementioned applications)
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Development, manufacture and commercialization of allogeneic
Natural Killer (NK) cell therapy products engineered to express a
therapeutic T cell receptor claimed in the Licensed Patent Rights for
the treatment or prevention of cancer in humans.
Specifically excluded from this field of use are Natural Killer T
(NKT) cell therapy products engineered via viral and non-viral means
for the treatment of human cancers, wherein the NKT cell therapy
product contains at least 50% NKT cells.''
Intellectual Property Group A is primarily directed to isolated T
cell receptors (TCRs) reactive to mutated Kirsten rat sarcoma viral
oncogene homolog (KRAS), within the context of several human leukocyte
antigens (HLAs). Mutated KRAS, which plays a well-defined driver role
in oncogenesis, is expressed by a variety of human cancers, including
pancreatic, lung, endometrial, ovarian and prostate. Due to its
restricted expression in precancerous and cancerous cells, this antigen
may be targeted on mutant KRAS-expressing tumors with minimal normal
tissue toxicity.
Intellectual Property Group B is primarily directed to isolated
TCRs reactive to mutated tumor protein 53 (TP53 or P53), within the
context of several HLAs. P53 is the archetypal tumor suppressor gene
and the most frequently mutated gene in cancer. Contemporary estimates
suggest that >50% of all tumors carry mutations in P53. Because of its
prevalence in cancer and its restricted expression to precancerous and
cancerous cells, this antigen may be targeted on mutant P53-expressing
tumors with minimal normal tissue toxicity.
Intellectual Property Group C is primarily directed to isolated
TCRs reactive to the E7 oncoprotein of Human Papilloma Virus (HPV) type
16, within the context of HLA-A*02. E7 oncoprotein drives malignant
transformation in HPV-infected cells. Due to its specific and
constitutive expression in cancer cells, this antigen may be targeted
in HPV-positive malignancies, such as cervical carcinoma and
oropharyngeal carcinoma, with minimal normal tissue toxicity.
Intellectual Property Group D is primarily directed to isolated
TCRs reactive to Melanoma-associated antigens 3, 6 and 12 (MAGE-A3/A6/
A12), within the context of multiple HLAs. There are twelve MAGE-A
superfamily antigens designated A1-A12. These antigens are among the
most commonly expressed cancer testis antigens in a variety of tumors
and are associated with poor disease prognosis. They are not expressed
on normal cells other than non-MHC expressing germ cells of the testis,
which do not generate an immune response. Thus, these antigens may be
targeted on MAGE-A-expressing tumors with minimal normal tissue
toxicity.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: December 23, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2022-28404 Filed 12-29-22; 8:45 am]
BILLING CODE 4140-01-P